Cybin
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cybin and other ETFs, options, and stocks.About HELP
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.
CEOEric So
CEOEric So
Employees50
Employees50
HeadquartersToronto, Ontario
HeadquartersToronto, Ontario
Founded2016
Founded2016
Employees50
Employees50
HELP Key Statistics
Market cap374.70M
Market cap374.70M
Price-Earnings ratio-1.94
Price-Earnings ratio-1.94
Dividend yield—
Dividend yield—
Average volume929.11K
Average volume929.11K
High today$7.79
High today$7.79
Low today$7.30
Low today$7.30
Open price$7.41
Open price$7.41
Volume571.70K
Volume571.70K
52 Week high$10.72
52 Week high$10.72
52 Week low$4.81
52 Week low$4.81
Stock Snapshot
Cybin(HELP) stock is priced at $7.49, giving the company a market capitalization of 374.7M. It carries a P/E multiple of -1.94.
As of 2026-01-11, Cybin(HELP) stock has fluctuated between $7.30 and $7.79. The current price stands at $7.49, placing the stock +2.6% above today's low and -3.8% off the high.
The Cybin(HELP)'s current trading volume is 571.7K, compared to an average daily volume of 929.11K.
In the last year, Cybin(HELP) shares hit a 52-week high of $10.72 and a 52-week low of $4.81.
In the last year, Cybin(HELP) shares hit a 52-week high of $10.72 and a 52-week low of $4.81.
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own HELP. This list is generated using Robinhood data, and it’s not a recommendation.